title: Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial.
abstract: OBJECTIVE
  Chronic constipation is a common gastrointestinal disorder. The aim of this study was to evaluate the efficacy, safety, and tolerability of tegaserod, a serotonin subtype 4 receptor partial agonist in patients with chronic constipation.
  
  
  METHODS
  This was a randomized, double-blind, placebo-controlled study. After a 2-week baseline, patients received tegaserod 2 mg twice daily (n = 450), tegaserod 6 mg twice daily (n = 451), or placebo (n = 447) for 12 weeks, followed by a 4-week withdrawal period. Responders were those patients having been treated for at least 7 days with an increase of > or =1 complete spontaneous bowel movement/week vs. baseline during weeks 1-4 (primary variable) and weeks 1-12 (secondary variable). Other secondary variables included patient assessment of constipation symptoms (number of bowel movements, stool form, abdominal bloating/distention, straining, and abdominal pain/discomfort), and global assessment of constipation and bowel habits.
  
  
  RESULTS
  Responder rates for complete spontaneous bowel movement during weeks 1-4 were significantly greater ( P < 0.0001) in the tegaserod 2 mg twice daily (41.4%) and 6 mg twice daily groups (43.2%) vs. placebo (25.1%). This effect was maintained over 12 weeks. Statistically significant improvements over placebo were observed across the majority of secondary variables for both tegaserod doses. No rebound effect was observed after treatment withdrawal. Tegaserod was well tolerated; headache and nasopharyngitis, the most frequent adverse events, were more common in the placebo group than in either tegaserod group.
  
  
  CONCLUSIONS
  Over 12 weeks, tegaserod treatment produced significant improvements in chronic constipation symptoms and was also safe and well tolerated.
authors.affiliation: University of Illinois College of Medicine, Rockford, IL, USA.
authors.forename: John F
authors.initials: JF
authors.lastname: Johanson
authors.forename: Arnold
authors.initials: A
authors.lastname: Wald
authors.forename: Gervais
authors.initials: G
authors.lastname: Tougas
authors.forename: William D
authors.initials: WD
authors.lastname: Chey
authors.forename: James S
authors.initials: JS
authors.lastname: Novick
authors.forename: Anthony J
authors.initials: AJ
authors.lastname: Lembo
authors.forename: Fiona
authors.initials: F
authors.lastname: Fordham
authors.forename: Mary
authors.initials: M
authors.lastname: Guella
authors.forename: Brigitte
authors.initials: B
authors.lastname: Nault
mesh_terms: D002908:Chronic Disease; D003248:Constipation / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D017366:Serotonin Receptor Agonists / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D005765:Gastrointestinal Agents; D007211:Indoles; D017366:Serotonin Receptor Agonists; C105050:tegaserod